tirzepatide surmount-1 nejm 2022 weight loss percent SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Tirzepatide vs. Semaglutide for Patients

(PDF 507 kb) Requirement of ER36 for the induction of ALDH1A1 expression in breast cancer cells treated with estrogen or tamoxifen (PDF 323 kb) Reduced self-renewal ability of ER36 + cells by ALDH1A1 knockdown (PDF 312 kb) The Correlation between ER36 Expression and ClinicopathologicalCharacteristics in Breast Cancer Patients from Cohort Chongqing (n=1 068 cases) (PDF 106 kb) Prognosis of Patients with ER36 + or ER36-Breast Cancer in Four Independent Cohorts (n=609) (PDF 124 kb) Multivariate Analyses of Disease-Free Survival (DFS) and Metastases-Free Survival (MSF) in 342 Patients with Breast Cancer Positive for Both ER36 and ER66 (PDF 155 kb) Responses of Tamoxifen Treatment to Patients with ER36 + or ER36 Breast Cancer in Four Independent Cohorts (PDF 125 kb) Responses of Patients with ER36 + Breast Cancer to Tamoxifen or Others in Four Cohorts (PDF 121 kb) Postmenopausal Breast Cancer Patient Groups Treated with Aromatase Inhibitors (AIs) and/or Tamoxifen with Tumors Expressing both ER36 and ER66 (n=244) (PDF 95 kb) Multivariate Analyses of Disease-Free Survival (DSF) and Metastasis-Free Survival (MSF) of Postmenopausal Patients with ER36 + /ER66 + breast cancer (PDF 161 kb) Rights and permissions This work is licensed under a Creative Commons Attribution 4.0 Unported License

S.BrayR.KindrackiZ.et al (2024)

The study found: Patients with diabetes who took semaglutide were more than four times more likely to develop NAION than those on other medications

See FDA prescribing information for semaglutide (Wegovy) and tirzepatide (Zepbound) via FDA Drugs@FDA

(The existing MDL is in the Eastern District of Pennsylvania under U.S